[Federal Register Volume 71, Number 219 (Tuesday, November 14, 2006)]
[Rules and Regulations]
[Pages 66231-66232]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E6-19203]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 558


New Animal Drugs for Use in Animal Feeds; Monensin

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule; technical amendment.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is amending the animal 
drug regulations to simplify the organization of special labeling 
requirements for formulations (Type A medicated articles, Type B and 
Type C medicated feeds) containing monensin sodium. This action is 
being taken to improve the clarity of the regulations.

DATES: This rule is effective November 14, 2006.

FOR FURTHER INFORMATION CONTACT:  Dragan Momcilovic, Center for 
Veterinary Medicine (HFV-226), Food and Drug Administration, 7519 
Standish Pl., Rockville, MD 20855, 240-453-6856, e-mail: 
[email protected].

SUPPLEMENTARY INFORMATION: On October 28, 2004, FDA approved a 
supplemental new animal drug application (sNADA 95-735) filed by Elanco 
Animal Health for RUMENSIN (monensin sodium) Type A medicated article 
adding use in a new class of cattle (dairy cows) for increased milk 
production efficiency (69 FR 68783, November 26, 2004). On December 15, 
2005, FDA approved another supplement to NADA 95-735 for use in dairy 
cow component feeding systems (71 FR 1689, January 11, 2006). The 
approval of each of these new conditions of use resulted in the 
amendment of the animal drug regulations for monensin in Sec.  558.355 
(21 CFR 558.355).
    Since these approvals for use of monensin in dairy cow feeds as 
well as beef cattle feeds, FDA has become aware of confusion regarding 
which statements on the approved Type A medicated article labeling also 
appear on the approved representative labeling (Blue Bird labeling) for 
Type B and Type C medicated feeds for each class of cattle. At this 
time, the regulations are being amended in Sec.  558.355 to simplify 
the organization of special labeling requirements for formulations 
(Type A medicated articles, Type B and Type C medicated feeds) 
containing monensin sodium. This action is being taken to improve the 
clarity of the regulations.
    Publication of this document constitutes final action on this 
change under the Administrative Procedures Act (5 U.S.C. 553). Notice 
and public procedure are unnecessary because FDA is merely correcting 
nonsubstantive errors.
    This rule does not meet the definition of ``rule'' in 5 U.S.C. 
804(3)(A) because it is a rule of ``particular applicability.'' 
Therefore, it is not subject to the congressional review requirements 
in 5 U.S.C. 801-808.

List of Subjects in 21 CFR Part 558

    Animal drugs, Animal feeds.

0
Therefore, under the Federal Food, Drug, and Cosmetic Act and under 
authority delegated to the Commissioner of Food and Drugs and 
redelegated to the Center for Veterinary Medicine, 21 CFR part 558 is 
amended as follows:

PART 558--NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS

0
1. The authority citation for 21 CFR part 558 continues to read as 
follows:

    Authority: 21 U.S.C. 360b, 371.

0
2. Amend Sec.  558.355 as follows:
    a. Revise paragraphs (d)(6) through (d)(11);
    b. Remove paragraph (d)(13); and
    c. Revise the second sentence of paragraph (f)(3)(xiii)(B), the 
third sentence of paragraph (f)(3)(xiv)(B), and the sixth sentence of 
paragraph (f)(6)(i)(b)(1).
    The revisions read as follows:


Sec.  558.355   Monensin.

* * * * *
    (d) * * *
    (6) All formulations containing monensin shall bear the following 
caution statement: Do not allow horses or other equines access to feed 
containing monensin. Ingestion of monensin by horses has been fatal.
    (7) Type A medicated articles containing monensin intended for use 
in cattle and goats shall bear, in addition to the caution statement in 
paragraph (d)(6) of this section, the following statements:
    (i) Monensin medicated cattle and goat feeds are safe for use in 
cattle and goats only. Consumption by unapproved species may result in 
toxic reactions.
    (ii) Feeding undiluted or mixing errors resulting in high 
concentrations of monensin has been fatal to cattle and could be fatal 
to goats.
    (iii) Must be thoroughly mixed in feeds before use.
    (iv) Do not feed undiluted.
    (v) Do not exceed the levels of monensin recommended in the feeding 
directions, as reduced average daily gains may result.
    (vi) Do not feed to lactating goats.
    (vii) If feed refusals containing monensin are fed to other groups 
of cattle, the concentration of monensin in the refusals and amount of 
refusals fed should be taken into consideration to prevent monensin 
overdosing.
    (viii) A withdrawal period has not been established for this 
product in pre-ruminating calves. Do not use in calves to be processed 
for veal.
    (ix) You may notice the following: Reduced voluntary feed intake in 
dairy cows fed monensin. This reduction increases with higher doses of 
monensin fed. Rule out monensin as the cause of reduced feed intake 
before attributing to other causes such as illness, feed management, or 
the environment. Reduced milk fat percentage in dairy cows fed 
monensin. This reduction increases with higher doses of monensin fed. 
Increased incidence of cystic ovaries and metritis in dairy cows fed 
monensin. Reduced conception rates, increased services per animal, and 
extended days open and corresponding calving intervals in dairy cows 
fed monensin. Have a comprehensive and ongoing nutritional, 
reproductive, and herd health program in place when feeding monensin to 
dairy cows.
    (x) Inadequate mixing (recirculation or agitation) of monensin 
liquid Type B or Type C medicated feeds has resulted in increased 
monensin concentration which has been fatal to cattle and could be 
fatal to goats.
    (8) Type A medicated articles containing monensin intended for use 
in chickens shall bear the caution statements specified in paragraphs 
(d)(6), (d)(7)(iii), and (d)(7)(iv) of this section.

[[Page 66232]]

    (9) Type B feeds containing monensin shall bear the statements 
specified in the following paragraphs of this section when intended for 
use in:
    (i) Cattle (as described in paragraphs (f)(3)(i) through 
(f)(3)(xii) of this section): See paragraphs (d)(6), (d)(7)(i) through 
(d)(7)(v), (d)(7)(vii), and (d)(7)(viii) of this section.
    (ii) Dairy cows (as described in paragraphs (f)(3)(xiii) and 
(f)(3)(xiv) of this section): See paragraphs (d)(6), (d)(7)(i) through 
(d)(7)(iv), (d)(7)(vii), (d)(7)(viii), and (d)(7)(ix) of this section.
    (iii) Goats: See paragraphs (d)(6) and (d)(7)(i) through (d)(7)(vi) 
of this section.
    (10) Type C feeds containing monensin shall bear the statements 
specified in the following paragraphs of this section when intended for 
use in:
    (i) Cattle (as described in paragraphs (f)(3)(i) through 
(f)(3)(xii) of this section): See paragraphs (d)(6), (d)(7)(i), 
(d)(7)(v), (d)(7)(vii), and (d)(7)(viii) of this section.
    (ii) Dairy cows (as described in paragraphs (f)(3)(xiii) and 
(f)(3)(xiv) of this section): See paragraphs (d)(6), (d)(7)(i), 
(d)(7)(vii), (d)(7)(viii), and (d)(7)(ix) of this section.
    (iii) Goats: See paragraphs (d)(6), (d)(7)(i), (d)(7)(v), and 
(d)(7)(vi) of this section.
    (11) Type B and Type C liquid feeds requiring recirculation or 
agitation that contain monensin and are intended for use in cattle 
(including dairy cows) and goats shall bear the caution statement 
specified in paragraph (d)(7)(x) of this section.
* * * * *
    (f) * * *
    (3) * * *
    (xiii) * * *
    (B) * * * See special labeling considerations in paragraph (d) of 
this section.
    (xiv) * * *
    (B) * * * See special labeling considerations in paragraph (d) of 
this section.
* * * * *
    (6) * * *
    (i) * * *
    (b) * * *
    (1) * * * See special labeling considerations in paragraph (d) of 
this section.
* * * * *

    Dated: October 31, 2006.
Stephen F. Sundlof,
Director, Center for Veterinary Medicine.
[FR Doc. E6-19203 Filed 11-13-06; 8:45 am]
BILLING CODE 4160-01-S